ArticleBMC neurology2026
The efficacy and safety of endovascular treatment for acute ischemic progressive stroke beyond 24 h.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the efficacy and safety of endovascular thrombectomy (EVT) for progressive stroke with large vessel occlusion (LVO) beyond 24 h.
methodsIn this retrospective cohort study, 122 Patients with progressive stroke due to LVO beyond 24 h were selected with Non-Contrast Computed Tomography (NCCT) head, and assigned to the EVT group (n = 61) and the Standard Medical Therapies (SMT) group (n = 61). The proportion of 90-day modified Rankin Scale (mRS) of 0-2, mRS score at discharge and 90-day mRS score, symptomatic intracranial hemorrhage (sICH) and mortality were compared between the two groups. Multivariate regression analysis was performed to assess whether EVT was an independent predictor of clinical outcomes.
resultsNo statistically significant differences were observed between the two groups in terms of age, sex distribution, history of hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, drinking, National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT (ASPECTS) scores at admission and at neurological deterioration, proportion of patients receiving intravenous thrombolysis (IVT), arterial occlusion site, discharge disposition or TOAST classification (all P > 0.05). The recanalization rate (modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b-3) of EVT reached 95.1%. Compared with SMT, the proportion of 90-day mRS of 0-2 in the EVT group was higher (60.66% vs. 40.98%, P = 0.046), while they had significantly lower mRS score at discharge (P = 0.003) and 90-day (P = 0.014). Multivariate logistic regression analysis demonstrated that the EVT group was the independent predictor of favorable 90-day outcome (mRS 0-2) (adjusted Odds Ratio (aOR) = 2.29, 95%CI: 1.05-5.12, P = 0.04). In addition, there was no statistical difference in the proportion of sICH (P = 0.119) and 90-day mortality between the two groups (P = 0.178).
conclusionThe study highlights the safety and effectiveness of EVT in LVO for progressive strokes beyond 24 h based on NCCT head. However, further high quality randomized trials are needed to confirm this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.